Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?

Hammond, Sean; Olsson‐Brown, Anna; Grice, Sophie; Naisbitt, Dean

doi:10.1111/cea.14134

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further to this, as discussed in Hammond et al, various investigational tools (LTTs, ELISpot etc.) are available for in vitro assessment of reactions and have been employed effectively to aid determination of causality in a safe and accurate manner in several reports to date. ,, Where the ICI is not the culpable agent, this may aid the successful reintroduction of the ICI in the absence of the offending therapeutic.…”

Section: Approaches To Address the Issue (Timing Drug Choice Patient ...mentioning

confidence: 99%

Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies

Grice,

Olsson-Brown,

Naisbitt

et al. 2024

Chem. Res. Toxicol.

Self Cite

View full text Add to dashboard Cite

With the rapid expansion in the development and clinical utility of immune checkpoint inhibitors (ICIs) for oncology, the continual evaluation of the safety profile of such agents is imperative. The safety profile of ICIs as monotherapy is dominated by immune-related adverse events, which can be considered as an extension of the mechanism of action of these immunomodulatory drugs. Further to this, an emerging theme is that ICI treatment can significantly impact upon the tolerability of coadministered medications. Numerous reports in literature indicate that ICIs may alter the immunological perception of coadministered drugs, resulting in undesirable reactions to a variety of concomitant medications. These reactions can be severe in manifestation, including hepatotoxicity and Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN), but may also have detrimental impact on malignancy control. To minimize the impact of such drug–drug interactions on patients, it is imperative to identify medications that may cause these reactions, understand the underlying mechanisms, consider the timing and dosing of comedication, and explore alternative medications with comparable efficacies. Improving our understanding of how concomitant medications affect the safety and efficacy of ICIs can allow for potential culprit drugs to be identified/removed/desensitized. This approach will allow the continuation of ICI therapy that may have been discontinued otherwise, thereby improving malignant control and patient and drug development outcomes.

show abstract

Section: Approaches To Address the Issue (Timing Drug Choice Patient ...mentioning

confidence: 99%

Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies

Grice,

Olsson-Brown,

Naisbitt

et al. 2024

Chem. Res. Toxicol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The DISI group contains contact allergy, fixed drug eruption (FDE), acute, generalized exanthematic pustulosis (AGEP), maculopapular rash (MPR), Stevens–Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) [ 11 , 13 ]. The hypersensitivity reactions may be regarded as a subcategory of irAEs in patients receiving ICIs [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Immune-checkpoint inhibitors (ICIs) are the most effective treatments nowadays. Nivolumab was the second ICI used for treating solid tumors with amazing results. Patients treated with Nivolumab may react differently to this treatment. Some people tolerate this treatment very well without experiencing any adverse reactions, whilst some may have mild symptoms and a part of them can present severe reactions. In our research, we sought to identify the answers to four questions: 1. what type of cancer has more severe hypersensitivity reactions to Nivolumab, 2. what is the time frame for developing these severe reactions to Nivolumab, 3. whether it is best to continue or stop the treatment after a severe hypersensitivity reaction to Nivolumab and 4. what severe hypersensitivity reactions are the most frequent reported along Nivolumab treatment. This review also highlights another problem with regard to the usage of concomitant and prior medications or other methods of treatment (e.g., radiation therapy), which can also lead to severe reactions. Treatment with Nivolumab is very well tolerated, but patients should also be warned of the possibility of severe hypersensitivity reactions for which they should urgently see a doctor for a personalized evaluation. There are some options for individuals with severe hypersensitivity reactions, for eg. switching the medication or applying a desensitization protocol.

show abstract

Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors

Yiu,

Aguilar-Duran,

Edwards

et al. 2024

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?

Cited by 6 publications

References 11 publications

Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies

Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature

Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors

Contact Info

Product

Resources

About